ELEVATED CONCENTRATIONS OF PLASMA-LIPIDS AND APOLIPOPROTEIN-B, APOLIPOPROTEIN-C-III, AND APOLIPOPROTEIN-E ARE ASSOCIATED WITH THE PROGRESSION OF CORONARY-ARTERY DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIC SWINE

被引:30
作者
HASLERRAPACZ, J
PRESCOTT, MF
VONLINDENREED, J
RAPACZ, JM
HU, ZL
RAPACZ, J
机构
[1] UNIV WISCONSIN, DEPT GENET, MADISON, WI 53706 USA
[2] UNIV WISCONSIN, DEPT MEAT & ANIM SCI, MADISON, WI 53706 USA
[3] CIBA GEIGY CORP, DIV PHARMACEUT, SUMMIT, NJ USA
关键词
SWINE; FAMILIAL HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; ANIMAL MODEL; APOLIPOPROTEINS;
D O I
10.1161/01.ATV.15.5.583
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We reported earlier that a complex familial hypercholesterolemia (c-FHC) phenotype characterized by elevated levels of total plasma cholesterol (TC) and apoB and reduced levels of HDL cholesterol (HDL-C) and apoA-I is associated with the development of spontaneous atherosclerotic lesions in swine. In this study, we investigated concentrations of plasma lipids and apolipoproteins B, C-III, and E in six parental animals of two cholesterol concentration phenotypes and their 32 offspring, which segregated into high, intermediate, and normal cholesterol phenotypes. Subsequently, we compared the extent of atherosclerotic lesion development in coronary arteries to the concentrations of plasma lipids and apolipoproteins in the parents and two offspring per family. Mean concentrations for the high (n=23), intermediate (n=13), and normal (n=2) cholesterol level phenotypes at 4 months of age were TC, 316 +/- 62.2, 159 +/- 17.1, and 105 +/- 12 mg/dL; LDL cholesterol, 275 +/- 63.1, 113 +/- 16.4, and 67 +/- 18.4 mg/dL; HDL-C, 35 +/- 6.1, 41 +/- 5.7, and 33 +/- 6.4 mg/dL; triglycerides, 48 +/- 10.8, 39 +/- 8.0, and 29 +/- 5.7 mg/dL; apoB, 152 +/- 32.5, 80 +/- 7.2, and 48 +/- 5.7 mg/dL; apoC-III, 10 +/- 4.2, 8 +/- 1.7, and 3 +/- 0.1 mg/dL; and apoE, 17 +/- 3.4, 7 +/- 1.7, and 5 +/- 0.7 mg/dL, respectively. Histological analysis of the major coronary arteries from members of the three families showed considerable variation in the severity of lesions, ranging from foci of adaptive intimal thickening consisting of two to six layers of smooth muscle cells to advanced lesions containing necrotic cores, cholesterol clefts, calcification, and hemorrhage (type V). The most extensive lesions occurred only in animals of the high cholesterol phenotype (ie, c-FHC), in which the concentration of TC and apoB progressively increased after 4 months of age, apoC-III, apoE, and triglycerides increased or remained elevated, and HDL-C decreased, except for one animal. Data presented here show that the plasma cholesterol phenotypes in FHC animals are associated with levels of apolipoproteins B, C-III, and E and indicate that the increases in the studied parameters after 4 months of age correlate with the progression of coronary artery disease.
引用
收藏
页码:583 / 592
页数:10
相关论文
共 41 条
[1]  
Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G., Hyperlipidemia in coronary heart disease, II: Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia, J Clin Invest, 52, pp. 1544-1568, (1973)
[2]  
Whayne T.F., Alaupovic P., Curry M.D., Lee E.T., Anderson P.S., Schlechter E., Plasma apolipoprotein B and VLDL, LDL and HDL-cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiography, Atherosclerosis, 39, pp. 411-424, (1981)
[3]  
Lusis A.J., Genetic factors affecting blood lipoproteins: The candidate gene approach, J Lipid Res, 29, pp. 397-429, (1988)
[4]  
Genest Jr. J.J., Martin-Munley S.S., McNamara J.R., Ordovas J.M., Jenner J., Meyers R.H., Silberman S.R., Wilson P.W.F., Salem D.N., Schaefer E.J., Familial lipoprotein disorders in patients with premature coronary artery disease, Circulation, 85, pp. 2025-2033, (1992)
[5]  
Kwiterovich P.O., Coresh J., Smith H.H., Bachorik P.S., Derby C.A., Pearson T.A., Comparison of the plasma levels of apolipoprotein B and A-I, and other risk factors in men and women with premature coronary artery disease, Am J Cardiol, 69, pp. 1015-1021, (1992)
[6]  
Mahley R.W., Innerarity T.L., Rall S.C., Weisgraber K.H., Plasma lipoproteins: Apolipoprotein structure and function, J Lipid Res, 25, pp. 1277-1294, (1984)
[7]  
Breslow J.L., Genetic basis of lipoprotein disorders, J Clin Invest, 84, pp. 373-380, (1989)
[8]  
Brown W.V., Baginsky M.L., Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein, Biochem Biophys Res Commun, 46, pp. 375-382, (1972)
[9]  
Wang C.-S., McConathy W.J., Kloer H.U., Alaupovic P., Modulation of lipoprotein lipase activity by apolipoproteins: Effect of apolipoprotein CIII, J Clin Invest, 75, pp. 384-390, (1985)
[10]  
Ginsberg H.N., Le N.-A., Goldberg I.J., Gibson J.C., Rubinstein A., Wang-Iversen P., Norum R., Brown W.V., Apolipoprotein B metabolism in subjects with deficiency of apolipoprotein CIII and AI: Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo, J Clin Invest, 78, pp. 1287-1295, (1986)